Biocept, Inc (BIOCQ) fair value: what the stock is really worth
We calculate from audited financials what Biocept, Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Biocept, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States.
Show more
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Stock analysis
Biocept, Inc (BIOCQ) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Biocept, Inc reported revenue of $25.9M in FY2022 versus $5.5M in FY2019, a compound +67.2%/yr. Reported net income was −$32.1M in FY2022.
Key figures
Market cap $262 · EPS (TTM) $−48.17 · Net margin −124% · Return on equity −187% · Return on assets (EBIT) −67.6% · Operating margin −1,038% · Revenue growth (YoY) −89.9% · Free cash flow −$14.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at 0%, BIOCQ screens richer than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−57.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.2%
’19
’20
’21
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−417.1% (2019) → −123.7% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biocept, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIOCQ
Frequently asked questions
Is Biocept, Inc (BIOCQ) overvalued or undervalued?
As of Sep 15, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of BIOCQ?
Our model-based fair value for Biocept, Inc is $0.0001 (as of Sep 15, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of BIOCQ?
Biocept, Inc has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biocept, Inc (BIOCQ)?
Our model-based price target is the fair value of $0.0001 (as of Sep 15, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Biocept, Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Biocept, Inc (BIOCQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biocept, Inc it is $0.0001 per share (as of Sep 15, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Biocept, Inc stock overvalued or undervalued in 2026?
As of Sep 15, 2026, BIOCQ trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOCQ?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Biocept, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biocept, Inc worth?
The market values Biocept, Inc at about $262 (market capitalisation, as of Sep 15, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
Which stocks are comparable to Biocept, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biocept, Inc stock attractive at the current price?
The data as of Sep 15, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 17/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOCQ calculated?
We run Biocept, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Biocept, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biocept, Inc (BIOCQ)?
The closing price on Sep 11, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biocept, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Biocept, Inc
How large is the market capitalisation of Biocept, Inc (BIOCQ)?
The market capitalisation of Biocept, Inc is $262. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Biocept, Inc (BIOCQ)?
Earnings per share at Biocept, Inc are $−48.17. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biocept, Inc (BIOCQ)?
The net margin of Biocept, Inc is −124% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biocept, Inc (BIOCQ)?
The return on equity (ROE) of Biocept, Inc is −187% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biocept, Inc (BIOCQ)?
On an EBIT basis the return on assets of Biocept, Inc is −67.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biocept, Inc (BIOCQ)?
The operating margin of Biocept, Inc is −1,038% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biocept, Inc (BIOCQ)?
Revenue at Biocept, Inc is growing −89.9% versus a year earlier (3y avg +67.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biocept, Inc (BIOCQ) generate?
The free cash flow of Biocept, Inc is −$14.1M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biocept, Inc (BIOCQ) hold?
Biocept, Inc holds more cash than debt, $788K net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biocept, Inc in the live analysis
One click puts Biocept, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 15, 2026